Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2Gastrointestinal 2Breast 2Thoracic 1Myeloid 1Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 182Magnetic Resonance Spectroscopy 161Specimen Handling 134enzalutamide 125Nivolumab 118Gemcitabine 96Docetaxel 92Radiosurgery 91Prednisone 81Androgen Antagonists 81Abiraterone Acetate 79Radiotherapy 75apalutamide 66Cisplatin 65darolutamide 62Ipilimumab 61Biopsy 61abiraterone 57cabozantinib 55Carboplatin 55Leuprolide 52enfortumab vedotin 50Radiation 47Pluvicto 45Standard of Care 44atezolizumab 41Surveys and Questionnaires 38acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
AP 1903 reagent × Genitourinary × 1 year × Clear all
NCT02744287 2026-02-23

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Regeneron Pharmaceuticals

Phase 1 Terminated
52 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡